Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age28-52
SponsorWeill Medical College of Cornell University

About this trial

This study will test whether gentle electrical stimulation to nerves near the uterus can reduce pelvic pain after uterine fibroid embolization. The investigators hypothesize that participants receiving active TUNES stimulation will experience lower pain levels and improved early recovery compared to those receiving sham stimulation or standard care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female, 28-52 years of age

Scheduled to undergo uterine fibroid embolization (UFE) at Weill Cornell Medicine

Able to provide informed consent

Willing to comply with all study procedures and follow-up

Disqualifiers

Known or suspected pregnancy

Active pelvic infection

History of pelvic inflammatory disease within the past 6 months

Implanted electrical device (e.g., pacemaker, neurostimulator)

Trial design

Design model

Parallel

Treatments tested in this trial

  • TUNES (Transmucosal Uterosacral Electrical Stimulation)

    Device

    The TUNES device delivers low-amplitude transvaginal electrical stimulation (0-10 mA, 80-120 Hz, 100-200 µs pulse width) through stainless steel electrodes embedded in a modified menstrual disc. The device targets sensory nerves near the uterosacral ligaments and Frankenhauser plexus involved in pelvic pain signaling. It is powered by an FDA-cleared portable TENS unit (TENS 7000®). The stimulation is administered in 20-minute sessions each hour for up to 12 hours following uterine fibroid embolization (UFE).

  • Sham TUNES Device

    Device

    A non-functioning version of the TUNES device that is identical in appearance, placement, and handling but delivers no electrical stimulation. It is used to maintain blinding and control for placebo effects.

Treatment groups

60 Participants
are divided into 3 treatment groups
Group A: Active TUNES DeviceExperimental treatment 1 intervention
Group B: Sham TUNES DeviceSham comparator 1 intervention
Group C: Standard Care ControlNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Mean number of patient-controlled analgesia (PCA) activations within 12 hours after uterine fibroid embolization

The mean number of patient-controlled analgesia (PCA) pump activations (button presses) within the first 12 hours after uterine fibroid embolization will be recorded. This measure reflects the frequency of patient-initiated pain medication use and serves as a quantitative indicator of post-procedural pain intensity. The mean number of activations will be compared across the active TUNES, sham TUNES, and control arms.

Time frame
Up to 12 hours post-UFE

Secondary outcomes

1

Mean stimulation intensity over time during TUNES therapy

For participants in the active and sham TUNES arms, the average stimulation intensity (measured in mA) will be recorded hourly during the 0-12 hour period following UFE. This measure assesses tolerance, comfort, and consistency of device use throughout this post-UFE window.

Time frame
0 to 12 hours post-UFE
2

Mean visual analog scale (VAS) pain score within 23 hours after uterine fibroid embolization

Pain intensity will be measured using a standard 0-10 visual analog scale (VAS), where 0 indicates no pain and 10 indicates the worst pain imaginable. VAS scores will be collected periodically during the first 23 hours post-UFE. The mean VAS score will be compared across the active TUNES, sham TUNES, and control arms to evaluate potential differences in perceived pain.

Time frame
Up to 23 hours post-UFE

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: